P
eyronie's disease (PD) is a connective tissue disorder characterised by the deposition of fibrous plaques within the tunica albuginea of the penis, resulting in penile shortening, curvature and gross disfigurement. It has been postulated to occur from a combination of trauma and genetic predisposition to abnormal wound healing. PD is associated with significant physical and psychological stress to the patient.
Pharmacological management of PD has faced considerable difficulty. The aim of treatment is to directly disrupt the inflammation and collagen plaque deposition, while minimising damage to the delicate surrounding neurovascular structures. A variety of treatment modalities have been trialled including oral/ topical medications, electromotive drug administration, extracorporeal shockwave therapy and intralesional injections. However, the effectiveness of these treatments is currently limited, with many patients eventually requiring surgery.
Currently, surgery remains the gold standard treatment. However, surgery is only indicated in patients with stable disease for at least 12 months and curvature that prevents penetrative sexual intercourse; and it carries significant risks of erectile dysfunction, penile shortening and sensory loss.
Collagenase clostridium histolyticum (CCH; Xiapex) is an isolated mixture of two microbial collagenases, AUX-I and AUX-II, contained in a phosphate buffer. Initially, an erection is induced in the patient via an intracavernosal injection of a vasoactive agent, allowing direct visualisation and manual palpation of the PD plaque. The area of maximum curvature is then determined and marked on the patient. A penile block is then administered using 10ml of clear lignocaine 1%, before a full vial of 0.9mg CCH is drawn up (preferentially into a hubless syringe with 0.01ml gradations). Once the penis is flaccid, the needle should be inserted through the width of the plaque, in line with the point of maximum concavity, and the entire dose of CCH is injected in multiple positions at the apex of the curvature (see Figure 1 ). Penile compression is applied and patients are given anti-inflammatory medication for two to three days. Patients are told to refrain from sexual intercourse and to keep the penis elevated for two weeks.
It is recommended that two to three days after the CCH injection, adjunctive treatments are used. These include manual modelling, stretching or use of a vacuum device. With manual modelling, when they achieve a spontaneous erection, patients are advised to gently bend the penis in the opposite direction to the PD curvature for 30 seconds. Stretching involves gentle manual stretching of the penis for 60 seconds after every urination. The vacuum pump is a mechanical device that should be used twice daily to mechanically stretch the penis; however, this should be done slowly and only to a moderate pressure to avoid complications.
The evidence base
Principally, an intralesional injectable agent must specifically degrade abnormal fibrous plaques without causing tunical damage, ensuring the preservation of tunical elasticity with a normal erection. There has been a significant history of intralesional injections with other agents in the management of PD, including interferon-α and verapamil. Both agents have demonstrated evidence of decreasing penile pain and curvature, but they did not translate effectively into routine clinical practice. Intralesional CCH has been proposed as a more effective treatment for PD than previous agents. It has been extensively evaluated through clinical trials and a number of high quality randomised trials have demonstrated the benefits of this therapy ( Furthermore, there was a reduction in penile plaque consistency after CCH injections and big improvements in sexual function as quantified by the IIEF to a statistically significant level. The efficacy demonstrated in these trials resulted in intralesional CCH gaining FDA approval for the treatment of PD with a palpable plaque and a curvature of >30° pre-treatment. 3 Levine et al conducted a phase III clinical trial of 347 patients also looking at mean reduction in penile curvature and PDQ/IIEF symptom scores with intralesional CCH. The results were robust, with 56% of patients achieving a decrease in penile curvature of at least 20%, and a concomitant decrease of one or greater points in the symptom bother domain of the PDQ. Overall mean decrease in penile curvature was 34% (−18.3° ± 14.02°) for all study participants. 4 However, current evidence fails to recognise the disparity between objective changes in curvature and how this translates to improvements in sexual function and the need for future surgery. Intralesional CCH is also associated with adverse effects (AEs). In a pooled data analysis of 1044 PD patients, 85.8% patients reported at least one treatmentrelated AE; most commonly bruising (82.7%), pain and swelling. Further analysis revealed the majority of AEs were mild (75.2%), with 14.2% experiencing no treatment-related AEs. Severe AEs were rare (five patients with penile haematoma, and four with corporal rupture). In addition, there were no immunogenicity-related hypersensitivity reactions. 5 Some patients will still not achieve sufficient symptomatic improvement, and in these cases surgical correction is required. There is currently a paucity of longitudinal experience with intralesional injections of CCH and its effects on future surgery are not well defined.
A small study of seven men who underwent salvage surgery with plaque excision and grafting (PEG) and/or tunica albuginea plication (TAP) following CCH treatment demonstrated that CCH was not a contraindication for future surgery in patients with PD. 6 The study showed comparable intraoperative times with standard PEG/TAP procedures (range: 88-146 mins). Furthermore, there were no reported anatomical difficulties or 7 However, despite these findings, the study did not clearly define all costs contributing to final analysis. In addition, an average of 7.2 injections per patient (rather than the standard eight) was used in calculations, which was identified from a pooled safety analysis of patients.
Conclusions
Intralesional CCH is a minimally invasive non-surgical alternative for the management of PD. We recognise the current limitations in the evidence base and the need for further studies characterising specific patient groups who will respond better, and also the establishment of a definitive treatment protocol. In addition, we recognise the need for further trials to show the impact CCH may have on the need for future surgery to make it a viable treatment option. Until then the importance of correct patient selection is imperative in avoiding ineffective and costly use of CCH injections.
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